Saxagliptin-13C2

Saxagliptin-13C2 (BMS-477118-13C2) is 13C labeled Saxagliptin. Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research[1][2][3].

Product Specifications

Product Name Alternative

BMS-477118-13C2

UNSPSC

12352005

Target

Dipeptidyl Peptidase; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Smiles

O=[13C](N1[C@]2([H])[C@@](C[C@H]1C#N)([H])C2)[13C@](C34CC5(CC(CC(C5)C4)C3)O)N

Molecular Formula

C16 13C2H24N3O2

Molecular Weight

316.39

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Chun-Jun Li, et al. Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro. Front Endocrinol (Lausanne) . 2017 Nov 27;8:326.|[3]Darshan J Dave. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011 Oct;2 (4) :230-5.|[4]Carolyn F Deacon, et al. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther. 2009 May;26 (5) :488-99.